Achilles Therapeutics is a UK based biopharmaceutical company developing personalised T-cell therapies targeting neoantigens in tumours. This client is headquartered at Catapult Stevenage, UK and this involvement is for a Phase 2 project. Achilles has over 85 employees behind their mission to deliver life saving T-cell therapies, with $138M in capital investment. In 2022 Achilles received 2 patents for their unique technologies contributing to the fight against cancer. Cell and Gene Therapy Catapult is the UK’s largest cell and gene manufacturing centre, providing a hub and world-class GMP facilities to foster the development of new, large-scale manufacturing systems and capabilities, helping companies to bring life-saving cell and gene therapies to market.
Achilles Therapeutics has stringent cGMP needs for an aseptic environment to safely process irreplaceable personalized T-cell therapies. Because of the personalized nature of these therapies, all aspects of the project requirements are critical to saving the patient’s life. The processing time for the cells is long, requiring thoughtful design accommodations for both ergonomic comfort and maximizing dexterity.
Read how Extract Technology worked with the Achilles Team’s URS to Engineer a high-end pharmacy isolator to safely process irreplaceable personalized T-cell therapies.